Q2 EPS Forecast for TuHURA Biosciences Lifted by Analyst

TuHURA Biosciences (NASDAQ:HURA) – Analysts at HC Wainwright raised their Q2 2026 earnings per share estimates for TuHURA Biosciences in a report released on Thursday, April 3rd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock.

A number of other brokerages have also recently commented on HURA. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Rodman & Renshaw started coverage on shares of TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price objective for the company.

TuHURA Biosciences Trading Up 7.7 %

Shares of NASDAQ:HURA opened at $3.64 on Monday. The business has a 50 day simple moving average of $3.41. TuHURA Biosciences has a twelve month low of $1.80 and a twelve month high of $7.93.

Hedge Funds Weigh In On TuHURA Biosciences

Several large investors have recently added to or reduced their stakes in the company. Apollon Wealth Management LLC bought a new stake in shares of TuHURA Biosciences during the 4th quarter valued at $253,000. Charles Schwab Investment Management Inc. purchased a new stake in TuHURA Biosciences in the 4th quarter worth $61,000. Suncoast Equity Management bought a new stake in TuHURA Biosciences during the fourth quarter valued at about $421,000. Accent Capital Management LLC purchased a new position in shares of TuHURA Biosciences in the fourth quarter valued at about $29,000. Finally, Hurlow Wealth Management Group Inc. bought a new position in shares of TuHURA Biosciences in the fourth quarter worth about $170,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.